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Abstract
Data availability expectations have changed over the years in scientific publishing, nowhere more so than in the
field of genomics. This field has spearheaded openness and transparency via public and structured deposition of
data. BMC Genomics strongly encourages deposition and unrestricted availability of all primary data underlying
research studies both as a way of ensuring reproducibility and standardisation, but also as part of overall
community-driven expectation on data deposition and sharing.
With funders and publishers moving towards more explicit mandates (regarding data availability), we examined the
current barriers to unrestricted availability of data and explored different scenarios in which commercial agreements
might run contrary to scientific convention and data sharing policies. In this editorial, Ross Tellam (CSIRO, Australia),
Paul Rushton (Texas A&M AgriLife Research) and Peter Schuerman (University of California, Merced), give their views
on the importance of data sharing and examine the current challenges in research fields like crop and livestock
genomics, where often it is necessary to integrate the interests of academic and commercial stakeholders. We discuss
the current approaches, highlight the importance of community-driven standards, and propose ways forward.
Why is providing access to data crucial?
RT - Scientific knowledge is cumulative and best used to
benefit all. This philosophy is deeply imbedded in our
societies as knowledge is the building foundation of each
generation and ultimately knowledge growth is the
inheritance of future generations. The publication of
scientific data is a long established and principal means
of dissemination of new knowledge and it also provides
a link to underpinning scientific principles that have
withstood the test of time. This process allows a wider
group of scientists to replicate and then importantly, ex-
tend knowledge in unanticipated directions. In the past,
data underwent minimal processing before it was pub-
lished and it could be easily replicated by others based
on information contained solely within the body of the
publication. This is now changing.
PR, PS - When reviewing a new manuscript for pos-
sible publication, a reviewer’s job is to assess the pre-
sented data and make a recommendation on publication
based on the data itself and the author’s interpretation
of the meaning of that data. So, it appears self-evident
that all data should be presented so that it can be accur-
ately assessed. Has the data been analysed correctly? Are
the conclusions drawn by the authors valid? Could the
experiments be repeated by an independent research
group and the data directly compared? Is the data in
such a form that it can later be used as the basis of com-
parisons with other data sets? Is there any possibility of
academic fraud?
However, the reality of data sharing is not so black
and white. Authors may see disadvantages in releasing
large data sets that have not yet been extensively ana-
lysed that could be further used by rival scientists. Com-
mercial sponsors may not wish to release large data sets
because they view the research sponsorship as an invest-
ment, and giving competitors access diminishes or elimi-
nates their return on investment.
Why is data sharing such an issue at present?
RT - Knowledge is rapidly increasing and evolving. This
is being driven by the scientific desire to address the
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complex questions of nature and is coupled with mark-
edly enhanced technical capability often involving
micro-scale analyses performed in massively parallel ar-
rays in multiple experimental dimensions intersecting
with increased computational and statistical capacities.
Genetics and genomics are at the forefront of these
changes [1].
Science is also moving from deterministic to more
probabilistic investigations. The former is exemplified in
genetics by a mutation of large effect where the presence
of the mutation in an individual causes a phenotype such
as a specific disease or developmental malformation.
The probabilistic approach is typified by population gen-
etics and multigenic traits, such as metabolic and disease
resistance traits, where a large number of interactive ge-
notypes each of small effect size contribute to an in-
creased risk of acquiring the trait in the population but
not necessarily in an individual. The scale of data gener-
ation in this latter instance is large particularly for gen-
omics technology.
What are the challenges to data deposition?
RT - The life sciences now face unique challenges in re-
lation to public access to ‘omics data. First, the sheer
quantity and scale of data is a practical issue in terms of
data transfer, storage, retrieval and maintenance [2].
However, large public access databases have been estab-
lished for most ‘omics technologies although these are
not universally used by scientists. The databases facili-
tate the deposition and internet-based redistribution of
data. They also provide considerable benefit to data gen-
erators who, with time, invariably want to free up com-
putational storage space and guard against accidental
data loss. Large datasets are also costly to generate and
often have unrealised scientific value. Hence, new collab-
orations and new research opportunities are facilitated
by data deposition as few large data sets are analysed to
their full potential. For some databases a depositor can
also be provided with a period of exclusive use of the
data thereby allowing them to maximally benefit from
their efforts.
What has been the general approach to address
problems with data deposition?
RT- The Human Genome Project, in its very early
stages, recognized the importance to the scientific com-
munity of large-scale data deposition in public access fa-
cilities while also preserving the rights of the data
generators to analysis and publication of their data in a
holistic fashion. This model has served us well and in-
deed it has been the catalyst for enhanced national and
international collaborations resulting in massive in-
creases in genomic and genetic knowledge over the last
25 years as well as new commercial enterprises [3–5].
PR, PS - Guided by the principle of peer review, and
to address the hesitation in releasing large data sets,
both federal agencies and journals have established pol-
icies on data sharing. While policies differ, in general,
there is currently a move towards making data available
as a condition of publication. Some publishers are mov-
ing towards mandating that all underlying data should
be shared. For example, Science instructs authors that
“All data necessary to understand, assess, and extend the
conclusions of the manuscript must be available to any
reader of Science” and goes on to add “appropriate data
sets… must be deposited in an approved database.”
However, these instructions are subject to interpretation.
Does the word “appropriate” mean that only a very small
portion of a large omics data set need be made available?
After all, only a small fraction is discussed in any detail.
Alternatively, does the expression “all necessary data” re-
quire that the large data set be deposited in its entirety?
Do you think mandating the sharing of data is
appropriate?
PR, PS – While it’s encouraging to see journals moving
in this direction and mandating data deposition [6] there
can be difficulties in explaining what is exactly required
[7, 8]. Increasingly there will be a trend for journals to
make data available as a condition of publication but the
devil is in the detail and the rules are often unclear.
Is there a “halfway” approach to data deposition?
PR, PS – A different approach is being taken by Scientific
Data [9]. Scientific Data aims to “address the increasing
need to make research data more available, citable, dis-
coverable, interpretable, reusable and reproducible.” Ra-
ther than mandating data sharing, this approach seeks to
reward scientists for releasing their data, and ensures data
quality adheres to community standards. The incentives
for scientists are that they produce a publication in a peer
reviewed journal and that they don’t have to present any
findings from the data, just the data itself. The review
process ensures that the data is of high quality and in
alignment with community standards, so other users of
the data also benefit.
GigaScience and F1000 Research have spearheaded
this trend since 2012, as a response to increasingly data-
driven research. In GigaScience, standard scientific pub-
lishing is linked directly to a database that harbours all
the relevant supporting data in a citable format.
What about sharing proprietary data, under
license agreements that limit its use?
PR, PS - Another layer of complexity is created when
researchers collaborate with companies. Data generated
in collaborative or sponsored research may have stra-
tegic benefits for the commercial partner, and releasing
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a data set into the public domain may not be in their
best interests.
No uniform approach or policy for data sharing is ap-
propriate to such collaborations. The solution lies in first
considering the needs of both parties regarding the dis-
position of the data – for example, the university’s need
to publish and the company’s need to get a return on
their investment. Next, creativity is required in balancing
those needs. While this is simple to say, in practice this
can be a challenge, unfortunately most universities have
historically repurposed their federal contracting infra-
structure to work with industry, which treats deal-making
like forms-processing and eliminates the opportunities for
creativity.
For example, at the outset of a collaboration discus-
sion, a company that is sponsoring research may want to
own all of the data that results from the research. The
investigator, however, may have different goals such as
publishing in a particular journal or set of journals. The
compromise may be to define certain categories of data
as having different sensitivities, or to de-identify certain
types of data, or to coordinate on patent filings before
releasing data – with the result being that both publica-
tion and proprietary benefit are achieved. Unless we
make room in our discussions for this type of creative
problem-solving and compromise, we run the risk of
failing to nurture relationships between academia and
industry.
RT- Many genomics technologies are now being applied
to commercially important agricultural populations, in
which elite germplasm is the primary commodity of value
[10]. Consequently there is strong reluctance of data gen-
erators to place genotypes in the public domain as these
directly relate to their commercial interests. It is inte-
resting to note that these commercial activities have fre-
quently grown out of genome sequencing projects, indeed
these commercial initiatives are one of the great successes
of these largely publicly-funded enabling projects [11].
The argument now emerging in some quarters, that these
commercial interests outweigh the need for primary data
deposition associated with scientific publication, is not lo-
gical or strong. There is no benefit to science if publica-
tions do not reveal primary underpinning data as the
study cannot be verified by replication and cannot be used
to direct science in new directions. The proposed scien-
tific publication should be subject to the normal standards
associated with data deposition and public access. If there
is commercial value in ‘omics data, especially genotype
data, then it can be held in private by the commercial in-
terests, although this precludes public benefit. One com-
promise is for databases to guarantee a limited period of
exclusivity to the data depositor. This model recognises
the important contributions of investigators and ensures
that commercial data do eventually become publicly
available for wider analysis. The relevant parties at the
commencement of the research should also discuss the
interplay between commercial reality and the freedom to
publish and then identify a pathway for mutual benefit.
This is especially important for the careers of young scien-
tists on short term contracts funded by industry.
Is data privacy a major issue for human data?
RT - Genotype data not only defines the individual it
also can define relatives and therefore agreements with
one party for public deposition of genotype information
can impact on other parties who have not agreed to pub-
lic release [12]. Hence, human data should be deposited
in databases where there is controlled access and con-
trolled conditions of use. Importantly, these databases
often have tiered levels of access that provide different
levels of confidentiality and control which can be nomi-
nated by the data depositor and therefore are well-suited
to the deposition of human data underpinning publica-
tions. It should be noted that the all pervasive use of
DNA sequencing technology for many experimental pur-
poses allows genotype to be deduced from indirect
sources e.g. via RNA-seq, Me-seq and ChIP-seq. These
possibilities reinforce the view that all human sequence
information in the public domain should not be linked
to individual identifiers.
How can funding agencies, publishers, and data
repositories help address these issues?
PR, PS - Universities are being asked to become more
engaged with companies and to translate more of their
research results into economic growth and job creation.
However we are also seeing new policies on data sharing
which may place limits on the creativity that can be de-
ployed in creating win-win arrangements. As we work to
balance our interests of promoting science and eco-
nomic development, broad-brush data sharing rules and
policies have the potential to hinder both. Federal agen-
cies and journals have a responsibility to consider their
rules and policies in this broader context.
Open data projects, such as the Human Genome Project
have had a substantial impact on the creation of jobs and
a massive influence on the economic returns to private
industry [13]. On a broader context, non-commercial ini-
tiatives such as the generation of GPS data provided clear
benefits to companies and spurred economic growth that
would not have been possible under restricted-use data
deposition.
RT - The international scientific community should
initially reach agreement on the minimum annotation
and quality standards for data deposition and then sup-
port long term funding for public access databases.
Ideally, the databases should not only store and dis-
tribute data but also provide flexible analytical tools to
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promote reanalysis. By structuring access, various levels
of confidentiality and time limited exclusive use can be
made available thereby removing barriers preventing
data from emerging into the public space. There are also
ethical responsibilities of users of the deposited data that
should be clearly articulated. Many databases are already
well established in this regard and indeed are leading
policy development in these areas.
Scientific publication is an efficient means of know-
ledge dissemination but there should be encouragement
of authors to place large scale datasets into the public
domain. The scientific community, public and data con-
tributor will all benefit. Of course, the real scientific
achievement is the conversion of these massive data
quantities into new knowledge. This is not an easy task
as there are few all encompassing conceptual frame-
works for data analysis in biology. The more people who
investigate these large datasets, the more likely these new
concepts will emerge – biological research needs them.
Some community-driven initiatives are already in place
to tackle quality standards in data deposition and curation
and this trend is being supported and encouraged by fun-
ders, with increasingly stronger mandates for open data
[14]. The Genomic Standards Consortium (http://gensc.org/)
has been formed to directly address the issues of trans-
parency and to develop a standardized approach to data
capture and exchange [15]. The ENCODE project has also
released minimum standards for many genomics tech-
nologies [16].
At BMC Genomics we believe that our data availability
policy should be led by researchers working within a
particular speciality. As such we recognise the import-
ance for researchers across genomics to have access to
data underlying studies published in our journal. We
therefore continue to strongly encourage all authors
who submit to our journal to deposit data from their
studies in publicly accessible repositories and will con-
tinue to reform our policies as the field inevitably edges
towards universal accessibility. As always, we very much
welcome your views and invite discussion.
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